Abstract
This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months.
Keywords:
Pertuzumab; brain metastasis; metastatic breast cancer.
Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Brain / drug effects
-
Brain / pathology
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / genetics
-
Brain Neoplasms / pathology
-
Brain Neoplasms / secondary
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / pathology
-
Breast Neoplasms / radiotherapy*
-
Combined Modality Therapy
-
Female
-
Humans
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / genetics
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Recurrence, Local / radiotherapy
-
Radiosurgery
-
Receptor, ErbB-2 / genetics
-
Trastuzumab / administration & dosage
Substances
-
Antibodies, Monoclonal, Humanized
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
pertuzumab
-
Trastuzumab